Image Analysis Group (IAG) is a London-headquartered imaging CRO founded in 2007, with offices and operational presence across the UK, Europe, the United States, India, China, and Australia. The company positions itself as a full-service imaging partner for pharmaceutical and biotechnology sponsors conducting clinical trials at every stage of development, from early phase to global pivotal studies.

IAG’s model combines a proprietary technology platform — DYNAMIKA™ — with a global network of specialist radiology readers and therapeutic experts to deliver centralised imaging services. The company has supported over 700 global clinical trials since its founding and works with clients ranging from emerging biotechs to large multinational pharmaceutical companies, including publicly announced partnerships with Takeda and a range of oncology and immunology-focused sponsors.

The company’s infrastructure is certified to ISO 13485 and SOC 2 Type II standards and is compliant with FDA 21 CFR Part 11, GDPR, and HIPAA, enabling it to serve sponsors across regulated global markets. IAG operates across North America, Europe, Asia-Pacific, Latin America, and Africa, with its headquarters at 12 Hammersmith Grove, London.

Key Products and Services

DYNAMIKA™ Platform

• Proprietary cloud-based imaging data management platform covering image capture, de-identification, transfer, quality control, and central review
• Built-in electronic Case Report Forms (eCRFs), adjudication workflows, and real-time sponsor dashboards for site performance and data quality monitoring
• AI-enabled image analysis, automated anonymisation, and structured quality control for regulatory-grade endpoints
• Configurable workflows with role-based access and integration with external EDC and eClinical systems
• Validated to FDA 21 CFR Part 11, ISO 13485, SOC 2 Type II, GDPR, and HIPAA

Trial Solutions

• Collect and Hold: Budget-efficient imaging data collection, quality control, and secure storage for studies not requiring immediate central review
• Early Phase Trials: Imaging strategy and operational delivery for Phase I and early Phase II studies, including pharmacodynamic readouts and mechanism-of-action assessment
• Late Phase Trials: Full iCRO services for global pivotal studies, including dual read, adjudication, and regulatory-submission-ready imaging packages
• Real-World Evidence (RWE) and AI Studies: Retrospective and prospective imaging data analysis, AI biomarker development, and companion diagnostic support

Central Image Review and Radiological Services

• Expert reader panels for indication-specific central reads applying established response criteria including RECIST 1.1, iRECIST, RANO/RANO 2.0, RAMRIS, Deauville, SPARCC, Kellgren–Lawrence, and others
• Dual read and adjudication workflows with structured inter-reader variability monitoring and calibration
• Quantitative and semi-quantitative imaging endpoint generation across MRI, CT, PET, DXA, ultrasound, and X-ray modalities

Therapeutic Imaging Expertise

Musculoskeletal: Bone health and osteoporosis (DXA, QCT, MRI), osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis

Oncology: Solid tumours, neuro-oncology (GBM/glioma), head and neck cancers, breast cancer, colorectal cancer, prostate cancer, lymphoma/myeloma, lung cancer, pancreatic cancer, and sarcomas; including radiomics and AI-enhanced tumour assessment

Autoimmune Diseases: Myositis, psoriatic arthritis, scleroderma (including the proprietary DAVIX MRI biomarker), SLE, and CAR-T therapy imaging in autoimmune indications

Obesity and Metabolic Diseases: Visceral and hepatic fat quantification, MASH/NASH (MRI-PDFF, MR elastography), rare metabolic disorders, and abdominal imaging

Rare Diseases: Rare metabolic and genetic disorders, Duchenne muscular dystrophy (quantitative MRI with Dixon imaging and T2 mapping), and paediatric imaging

Neuro-Imaging: Neuro-oncology, traumatic brain injury, stroke, and neuropsychiatric disorders

IAG occupies a focused niche within the CRO landscape as a dedicated imaging CRO — a category distinct from full-service CROs in its depth of modality expertise, reader network, and purpose-built technology infrastructure. The DYNAMIKA™ platform differentiates IAG by integrating imaging data management, quality control, and central review within a single validated system, reducing the fragmentation common in multi-vendor imaging programmes. The company’s scientific credentials are reinforced by its stated standing amongst the top 2% of researchers by publication impact in neuro-oncology radiology, and its experience across over 700 trials positions it as a credible partner for sponsors seeking specialist imaging capability from first-in-human through to regulatory submission.